Innovative machine-learning approach for future diagnostic advances in Parkinson’s disease » Luxembourg Institute of Health
Home » News » Innovative machine-learning approach for future diagnostic advances in Parkinson’s disease

Press Release

Innovative machine-learning approach for future diagnostic advances in Parkinson’s disease

12 November 2020 6minutes

Luxembourg Institute of Health (LIH) scientists identify mitochondria interactions as a novel biomarker to classify PD patients

In a new study led by the Immune Systems Biology research group of the LIH Department of Infection and Immunity, researchers adopted a holistic machine-learning approach to elucidate how the interactions between neuronal mitochondria can serve as a powerful tool to distinguish nerve cells from Parkinson’s patients from those belonging to healthy subjects, thereby providing new insights in the pathogenesis, diagnosis and treatment of this neurodegenerative disorder. The results were published today in the renowned journal ‘Nature Partner Journals Systems Biology and Application’.

Parkinson’s disease (PD) is the second most common neurodegenerative disease, with patient numbers being expected to double worldwide in the next 20 years. The detailed molecular and cellular mechanisms underlying its pathogenesis remains unclear, although recent evidence has pointed towards the role of mitochondrial dysfunction in the onset of the disease. Mitochondria — small cellular ‘subunits’ involved in cell metabolism and energy generation — constantly and dynamically interact with each other, forming perpetually changing networks known as mitochondria interaction networks (MINs). The researchers therefore sought to understand the correlation between the mitochondrial impairments observed in PD and any specific network topological changes in MINs, with the aim of advancing the early diagnosis and classification of PD patients.

“Since conventional analysis focusing on individual mitochondria has not provided satisfying insights into PD pathogenesis, our pioneering work has gone a step forward by investigating the interaction networks between these organelles”, explains Dr Feng He, Group Leader of the Immune Systems Biology Group of the LIH Department of Infection and Immunity and corresponding author of the publication.

Leveraging their strong expertise in network analysis and machine learning, the scientists analysed a large 700 Gigabyte dataset of three-dimensional mitochondrial images of colonic neurons, collected from PD patients and healthy controls, and dopaminergic neurons, derived from stem cells. They found that particular network structure features within MINs were altered in PD patients compared to controls. For instance, in PD patients, mitochondria formed connected subnetworks that were generally larger than in healthy individuals. In line with this result, the efficiency of the energy and information transmission and distribution among the different mitochondria in PD patient MINs was significantly lower than in controls, suggesting that the longer ‘transmission delays’ were associated with the larger diameter of the components of the MINs observed in PD subjects.  “These different topological patterns in MINs may mean that energy and information are possibly produced, shared and distributed less competently in the neuronal mitochondria of PD patients relative to healthy controls, suggesting their connection to mitochondrial damage, deficiencies and fragmentation typical of neurodegenerative disorders”, adds Dr He.

Moreover, the research team found these different MIN patterns to be highly correlated with the commonly-used PD clinical scores of individual patients, i.e. the Unified Parkinson’s Disease Rating Scale (UPDRS). Indeed, when applying a machine learning approach to analyse these MIN characteristics, the researchers observed that the use of a combination of those network features alone allowed them to accurately distinguish between PD patients and healthy controls.

“Our findings bring forward the potential of using particular mitochondrial network features as novel biomarkers for the early diagnosis and classification of PD patients, which might help develop a new health index. As a next step, we will explore how our results may offer new perspectives for the understanding of various other neurodegenerative diseases characterised by mitochondrial dysregulation, such as Huntington disease and Alzheimer’s, making our work a true instance of translational and transversal research”, states Prof Rejko Krüger, Director of Transversal Translational Medicine at LIH and contributing author of the study. 

“This publication also constitutes a major step forward in the application of advanced machine-learning techniques to unravel the complex network interactions of cellular organelles for disease stratification. Indeed, data analytics and innovative digital technologies are a core priority area for our department and for LIH as a whole”, concludes Prof Markus Ollert, Director of the Department of Infection and Immunity and contributing author of the paper.

The inter-disciplinary study relied on the close cooperation between clinicians, neuroscientists, network biologists, big data and machine learning experts from the Luxembourg Institute of Health (LIH), the Luxembourg Centre for Systems Biology (LCSB) and the Central Hospital of Luxembourg (CHL), particularly via clinical neurologist Dr Nico Diederich, as well as on the collaboration with other international partners such as the Instituto de Física Interdisciplinar y Sistemas Complejos IFISC (Spain).

The findings were published in November 2020 in the prestigious international journal Nature Partner Journals Systems Biology and Applications, with the full title “Mitochondria interaction networks show altered topological patterns in Parkinson’s disease”.

Machine-learning based analysis of mitochondria interaction networks


This study was supported by grants from the Luxembourg National Research Fund (FNR) under the CORE programme (CORE/14/BM/8231540/GeDES), FNR AFR-RIKEN bilateral programme (TregBAR) and PRIDE programme (PRIDE/11012546/NEXTIMMUNE and PRIDE/10907093/CRITICS). Prof Krüger’s work on the National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD) is supported by the FNR PEARL programme. The work was also partially supported through intramural funding of LIH and LCSB through the Luxembourg Ministry of Higher Education and Research (MESR). The cooperation was achieved through the European Cooperation in Science and Technology (eCOST) Action CA15120 Open-MultiMed. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 851255) and from the Spanish State Research Agency through the Severo Ochoa and María de Maeztu Program for Centers and Units of Excellence in R&D (MDM-2017-0711).

The study was performed in close collaboration with national and international partners, and involved LIH’s Department of Infection and Immunity (DII), LIH’s Transversal Translational Medicine unit, the Centre Hospitalier de Luxembourg (CHL), the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg, the Instituto de Fiśica Interdisciplinar y Sistemas Complejos IFISC (Spain), the Center for Biomedical Technology at the Universidad Politécnica de Madrid (Spain), the Department of Dermatology and Allergy of the Odense Research Center for Anaphylaxis (ORCA) at the University of Southern Denmark (Denmark) and the Institute of Medical Microbiology at the University Hospital Essen of the University Duisburg-Essen (Germany).


The Luxembourg Institute of Health (LIH) is a public research organization at the forefront of biomedical sciences. With its strong expertise in population health, oncology, infection and immunity as well as storage and handling of biological samples, its research activities impact on people’s health. At LIH, devoted scientists investigate disease mechanisms to develop new diagnostics, innovative therapies and effective tools to implement personalized medicine.

Scientific Contact

  • Dr Feng
    Group Leader, Immune Systems Biology

    Department of Infection and Immunity Luxembourg Institute of Health


Press Contact

  • Arnaud
    Head of Marketing and Communication

    Luxembourg Institute of Health



Related News